PDA Technical Report 82: A Comprehensive Guide to Low Endotoxin Recovery (LER)
The prevailing theory, as discussed in TR 82, is that the combination of chelating agents and surfactants alters the physical structure of the endotoxin micelle, hiding the Lipid A portion (the toxic part) from the LAL reagent. The endotoxin is not destroyed; it is simply , making it undetectable by traditional endotoxin testing methods (BET). 3. Key Guidance on LER Hold-Time Study Design
: Spiked samples are held at multiple temperature conditions (e.g., 2–8°C and 20–25°C) and tested at sequential intervals over several days or weeks. pda technical report 82
PDA Technical Report 82 dives into the latest improvements in programmable device architectures, highlighting practical design patterns, performance benchmarks, and deployment lessons for embedded and edge systems. The report covers:
This "masking" is typically a time- and temperature-dependent process driven by specific formulation components, most notably the combination of and chelating agents (like citrate or phosphate buffers). These components cause the endotoxin lipopolysaccharides (LPS) to form macromolecular complexes that the LAL reagents cannot recognize, leading to potentially false-negative results. Core Components of TR 82 PDA Technical Report 82: A Comprehensive Guide to
PDA has officially announced a , with a team being assembled as of 2025 to “update its content to make it a valuable resource for PDA members and align with current practices and science”. The revision team seeks subject matter experts in microbiology, sterile processing, and ATMP/gene and cell therapy—reflecting the expanding scope of biologic products requiring LER evaluation.
Published in March 2019, , titled Low Endotoxin Recovery , is a definitive industry resource for addressing one of the most challenging phenomena in modern biopharmaceutical quality control. Key Guidance on LER Hold-Time Study Design :
PDA Technical Report 82 (TR 82), released in March 2019, provides definitive industry guidance for detecting and managing Low Endotoxin Recovery (LER) in biopharmaceutical products. It establishes standardized protocols for conducting hold-time studies and outlines strategies for addressing endotoxin masking in, for example, monoclonal antibody formulations. For more details, visit Lonza . PDA technical report on low endotoxin recovery | Lonza
As the industry looks toward a potential revision of TR 82 after 10 years of collective experience, how is your team managing the LER challenge? 🧪
Endotoxins are lipopolysaccharides (LPS) derived from the outer membranes of Gram-negative bacteria. In their natural state, these amphiphilic molecules aggregate into supramolecular structures (micelles or vesicles). Standard compendial assays, such as the Limulus Amebocyte Lysate (LAL) test, rely on these aggregates to trigger an enzymatic clotting cascade. Cell Culture FAQs: Bacterial Endotoxin Contamination
Low Endotoxin Recovery refers to the inability to recover a known, spiked concentration of endotoxin over time when added to an undiluted drug substance or drug product. PDA TR 82 provides a formal definition: LER is the when a known amount of endotoxin is added to an undiluted product.